作者: Thomas Schirrmann , Michael Hust
DOI: 10.1007/978-1-60761-786-0_11
关键词:
摘要: Recombinant antibodies as therapeutics offer new opportunities for the treatment of many tumor diseases. To date, 18 antibody-based drugs are approved cancer and hundreds anti-tumor under development. The first clinically were murine origin or human-mouse chimeric. However, since antibody domains immunogenic in human patients could result anti-mouse (HAMA) responses, currently mainly humanized fully developed therapeutic applications.Here, vitro selection technologies directly allow corresponding genes from gene libraries. Antibody phage display is most common way to generate has already yielded thousands recombinant research, diagnostics therapy. Here, we describe methods construction scFv libraries selection.